New, Non-Invasive, Visual-Field Testing Device
FDA-cleared objective device, objectiveFIELD, tests both eyes open simultaneously in a non-contact manner. objectiveFIELD is easy to administer and takes a few minutes to complete different examinations including normal, glaucoma, macular degeneration, diabetic retinopathy, multiple sclerosis, epilepsy, migraine, concussion, and other neuro-vision conditions. This story is related to the following:Medical Devices (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - October 12, 2018 Category: Medical Devices Source Type: news

Green, leafy vegetables can decrease your risk of glaucoma by 20%
(Natural News) Research provides another reason for you to eat more leafy greens: They prevent the onset of a serious eye disease called glaucoma. In a study published in the journal JAMA Ophthalmology, researchers suggested that eating green leafy vegetables every day may cut one’s risk of glaucoma by 20 to 30 percent over many years.... (Source: NaturalNews.com)
Source: NaturalNews.com - October 7, 2018 Category: Consumer Health News Source Type: news

Placing a Bypass Stent During Cataract Surgery Cuts Need for Glaucoma Eyedrops Placing a Bypass Stent During Cataract Surgery Cuts Need for Glaucoma Eyedrops
Implantation of the iStent Trabecular Micro-Bypass in conjunction with cataract surgery is associated with reduced need for glaucoma eyedrops, according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - October 5, 2018 Category: Surgery Tags: Ophthalmology News Source Type: news

FDA Clears New Form of Latanoprost (Xelpros) for Glaucoma FDA Clears New Form of Latanoprost (Xelpros) for Glaucoma
Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride, a preservative commonly used in topical ocular preparations.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Exercise found to protect your eyesight
(Natural News) Looking for ways to maintain your good eyesight? According to a study conducted by researchers from the University of California, Los Angeles, people who take part in moderate to intense physical activity have the capacity to curb their chances of developing glaucoma. The results of the research, presented at the 121st Annual Meeting... (Source: NaturalNews.com)
Source: NaturalNews.com - September 17, 2018 Category: Consumer Health News Source Type: news

(S)pot Check on Alternative Treatments for Glaucoma (S)pot Check on Alternative Treatments for Glaucoma
Does marijuana, gingko biloba, or bilberry effectively manage symptoms of glaucoma?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 17, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension
MUMBAI, India& PRINCETON, N.J.--(BUSINESS WIRE) September 14, 2018 --Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) today announced U.S. Food and Drug Administration (USFDA) approval for the New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2018 Category: Drugs & Pharmacology Source Type: news

How suppliers are taking drug-delivery tech to the next level
Medical device industry suppliers and outsourcers are helping to enable the latest drug-delivery tech. Various cardiac pacing components that can be loaded with a steroid to minimize fibrous encapsulation. [Image courtesy of ProMed Pharma LLC]Drug-eluting technologies are moving beyond stents, thanks in part to the development of polymeric hydrogels engineered to respond to a range of different physical and chemical stimuli. Medtech innovators have figured out how to use hydrogels as components of micro-shells or nanoparticles to assist with controlled, long-term drug delivery. They’ve also figured out how to take so...
Source: Mass Device - September 14, 2018 Category: Medical Devices Authors: Heather Thompson Tags: Contract Manufacturing Drug-Device Combinations Stents Freudenberg Medical Lubrizol LifeSciences promedpharma Trelleborg Sealing Solutions Source Type: news

Alcon Pulls CyPass Glaucoma Micro-Stent Off the Global Market Alcon Pulls CyPass Glaucoma Micro-Stent Off the Global Market
The company cites 5-year safety data that show statistically significant endothelial cell loss in patients who received the CyPass stent at the time of glaucoma surgery.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Alcon withdraws all CyPass micro-stents, says it will not affect spin-off
Novartis (NYSE:NVS)’s Alcon said this week it is voluntarily withdrawing its CyPass micro-stents from the global market, but that the withdrawal will not affect its planned spin-out. The decision to pull the devices comes off the analysis of five-year post-surgery data from the Compass-XT study of the device, which showed that patients treated with the stent had statistically significant loss of endothelial cells as compared to a control group. Endothelial cells are believed to be vital in maintaining visual functionality. The company advised surgeons to immediately cease further implantation of the devices...
Source: Mass Device - August 31, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Alcon Novartis Source Type: news

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma
Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FDA) approved the CyPass Micro-Stent in July 2016 for use in conjunction with cataract surgery in adult patients with mild-...
Source: Food and Drug Administration - August 31, 2018 Category: Food Science Source Type: news

Alcon Pulls CyPass Micro-Stent from Market Based on Long-Term Safety
One company's loss is another company's gain today in the increasingly competitive microinvasive glaucoma surgical (MIGS) market.  Alcon, a division of Novartis, said it is voluntarily removing all versions of the Cypass Micro-Stent from the global market based on a new analysis of five-year post-surgery data. The COMPASS-XT long-term safety data showed that at five years, patients in the CyPass Micro-Stent group experienced statistically significant endothelial cell loss compared to patients who underwent cataract surgery alone. The news sent shares of Glaukos, one of the main competitors in the MI...
Source: MDDI - August 29, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

Novartis says glaucoma stent setback will not derail Alcon spin-off
Novartis' eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans to spin off the unit next year. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Open-Angle Glaucoma in One Eye Likely to Develop in the Other Open-Angle Glaucoma in One Eye Likely to Develop in the Other
Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Staying Fit Might Cut Glaucoma Risk Staying Fit Might Cut Glaucoma Risk
Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

New Treatments for Aging Eyes: Cataracts, Glaucoma, More
Learn how advances such as replacement lenses and gene therapy offer hope for those losing vision from eye conditions such as cataracts and glaucoma. (Source: AARP.org News)
Source: AARP.org News - August 20, 2018 Category: American Health Source Type: news

Staying fit might cut glaucoma risk
(Reuters Health) - Meeting physical activity guidelines and being physically fit may reduce the risk of developing glaucoma by 40 percent to 50 percent, recent research suggests. (Source: Reuters: Health)
Source: Reuters: Health - August 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

T-Cell Immune Responses Drive Neurodegeneration in Glaucoma T-Cell Immune Responses Drive Neurodegeneration in Glaucoma
Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

FDA Clears Hydrus Microstent for Glaucoma FDA Clears Hydrus Microstent for Glaucoma
The Hydrus microstent used in conjunction with cataract surgery achieves significant and sustained lowering of intraocular pressure in patients with primary open-angle glaucoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

Three Eye Conditions Linked to Higher Alzheimer's Risk Three Eye Conditions Linked to Higher Alzheimer's Risk
More insight into the eye as a'window into the brain'comes from a study linking glaucoma, age-related macular degeneration, and diabetic retinopathy to a higher risk for Alzheimer's disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Medical News Today: Vision loss in glaucoma may be due to immune response
Glaucoma is a condition that leads to progressive loss of vision, but its root causes remain unclear. New research says an immune response may be to blame. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 14, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

ME & MY OPERATION: The tap in the eye that could stop glaucoma patients from losing their sight
Glaucoma affects 300,000 people in the UK and is a leading cause of blindness. Here, Bernie Pedley, 73, from Preston, Lancashire, tells her story of life-changing surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2018 Category: Consumer Health News Source Type: news

Ivantis Now Has Its MIGS Stent Approved
The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete against Glaukos’ iStent. Irvine,CA-based Ivantis’ approval comes on the heels of Glaukos winning a nod from FDA for the iStent inject Trabecular Micro-Bypass System. The Hydrus Microstent is used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The device’s approval is based on the HORIZO...
Source: MDDI - August 13, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

FDA approves Ivantis ’ Hydrus microstent
Ivantis said today it won FDA approval for its Hydrus microstent designed to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The Hydrus microstent is designed for minimally invasive microsurgical procedures to reduce eye pressure in patients with glaucoma. The device is multi-modal, the company said, by creating a large opening through the trabecular meshwork and dilating and scaffolding the conventional pathway through which fluid exits the eye. Approval came based on results from the Horizon trial, which the Irvine, Calif.-based company touted as the largest min...
Source: Mass Device - August 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Ivantis Source Type: news

New Research Suggests Glaucoma May Be an Autoimmune Disease
Title: New Research Suggests Glaucoma May Be an Autoimmune DiseaseCategory: Health NewsCreated: 8/10/2018 12:00:00 AMLast Editorial Review: 8/13/2018 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - August 13, 2018 Category: Opthalmology Source Type: news

Study Links 3 Eye Diseases, Alzheimer's
Patients with age-related macular degeneration, diabetic retinopathy or glaucoma had a 40 to 50 percent greater risk of Alzheimer's disease than those without the eye conditions, the authors of a new study report. (Source: WebMD Health)
Source: WebMD Health - August 12, 2018 Category: Consumer Health News Source Type: news

New Research Suggests Glaucoma May Be an Autoimmune Disease
FRIDAY, Aug. 10, 2018 -- The eye disease glaucoma may be an autoimmune disorder, a new study suggests. Glaucoma affects nearly 70 million people worldwide. It damages the retina and optic nerve and can lead to blindness. In research with mice,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 10, 2018 Category: General Medicine Source Type: news

Autoimmune response drives vision loss in glaucoma
(Massachusetts Eye and Ear Infirmary) A research team from Massachusetts Eye and Ear and MIT has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world. The findings, published online in Nature Communications, suggest that high pressure in the eye leads to vision loss by setting into motion an autoimmune response that attacks the neurons in the eye. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 10, 2018 Category: International Medicine & Public Health Source Type: news

Study suggests glaucoma may be an autoimmune disease
(Massachusetts Institute of Technology) A new study from MIT and Massachusetts Eye and Ear finds glaucoma may be an autoimmune disorder, mediated by T cells that target heat shock proteins in the retina. The discovery suggests it could be possible to develop new treatments for glaucoma by blocking this autoimmune activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 10, 2018 Category: International Medicine & Public Health Source Type: news

Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to Do
Title: Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to DoCategory: Health NewsCreated: 8/7/2018 12:00:00 AMLast Editorial Review: 8/8/2018 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - August 8, 2018 Category: Opthalmology Source Type: news

Eye conditions provide new lens screening for Alzheimer's disease
(University of Washington Health Sciences/UW Medicine) A study of 3,877 randomly selected patients found a significant link between three degenerative eye diseases -- age-related macular degeneration, diabetic retinopathy and glaucoma -- and Alzheimer' disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 8, 2018 Category: International Medicine & Public Health Source Type: news

Are The Health Benefits Of Turmeric Too Good To Be True?
(CNN) — Alzheimer’s disease. Diabetes. Arthritis. Unwanted hair growth. Baldness. Infertility. Erectile dysfunction. Hangovers. Glaucoma. Cancer. If you have an ailment, there’s a good chance that someone, somewhere, is studying whether turmeric can treat it. There are more than 15,000 manuscripts published about curcumin, the active ingredient in turmeric, and about 50 manuscripts added to this collection each week, according to the National Institutes of Health. “It’s really taken on sort of panacea-like properties in terms of the things it’s being studied for and the things it has bee...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 7, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local TV turmeric Source Type: news

Have Glaucoma and Need to Switch Eye Docs? Here's What You Need to Do
TUESDAY, Aug. 7, 2018 -- If you have glaucoma and need to find a new ophthalmologist, creating a personal data portfolio will help ensure a smooth transition in the care of your eye disease. The Glaucoma Research Foundation suggests the portfolio... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 7, 2018 Category: General Medicine Source Type: news

Glaukos inks R & D deal for glaucoma therapy
Glaukos (NYSE:GKOS) has inked a research & development deal with Japanese biotech D. Western Therapeutics Institute to develop an intraocular glaucoma therapy. Glaukos and DWTI plan to evaluate products from the biotech’s compound library, as well as potentially synthesize new compounds as a part of the collaboration. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos inks R&D deal for glaucoma therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat Glaukos Source Type: news

American Academy of Ophthalmology launches new scientific journal dedicated to glaucoma research
(American Academy of Ophthalmology) The American Academy of Ophthalmology today announced the launch of Ophthalmology ® Glaucoma, a new scientific journal focused exclusively on glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2018 Category: International Medicine & Public Health Source Type: news

Durham pharma could be on its way to second FDA approval
Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) could be well on its way to a second U.S. Food and Drug Administration approval.   The FDA has accepted Aerie’s new drug application (NDA) submission for the company’s second glaucoma drug, Roclatan, earlier than expected.  Aerie said this week that the FDA has set a goal date for completion of the agency’s review of the Roclatan NDA of March 14, 2019. The NDA acceptan ce comes less than three months after Aerie said it had launched its first… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 26, 2018 Category: Health Management Authors: Jennifer Henderson Source Type: news

Durham pharma could be on its way to second FDA approval
Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) could be well on its way to a second U.S. Food and Drug Administration approval.   The FDA has accepted Aerie’s new drug application (NDA) submission for the company’s second glaucoma drug, Roclatan, earlier than expected.  Aerie said this week that the FDA has set a goal date for completion of the agency’s review of the Roclatan NDA of March 14, 2019. The NDA acceptan ce comes less than three months after Aerie said it had launched its first… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 26, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

Turmeric extract in eye drops could treat the early stages of glaucoma
Curcumin, extracted from the yellow spice turmeric, could be used in eye drops to treat the early stages of glaucoma, found a new study led by MRC-funded researchers. (Source: Medical Research Council General News)
Source: Medical Research Council General News - July 25, 2018 Category: Research Source Type: news

How turmeric could offer hope for millions with glaucoma
University College London and Imperial College London trials showed eye drops containing curcumin, responsible for turmeric's yellow colour, slashed the loss of crucial retinal cells in rats. (Source: the Mail online | Health)
Source: the Mail online | Health - July 25, 2018 Category: Consumer Health News Source Type: news

Medical News Today: How a turmeric compound could treat glaucoma
Glaucoma can lead to vision loss, but a turmeric derivative can improve current treatments. New research devises a viable method of adding it to eye drops. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 25, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Turmeric derivative in drops may treat glaucoma
Adding an extract from the yellow spice turmeric into eye drops was effective in treating early stages of glaucoma in a study with rats. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 24, 2018 Category: Consumer Health News Source Type: news

Turmeric eye drops could treat glaucoma
(University College London) A derivative of turmeric could be used in eye drops to treat the early stages of glaucoma, finds a new study led by UCL and Imperial College London researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 23, 2018 Category: International Medicine & Public Health Source Type: news

Gene regulator may contribute to protein pileup in exfoliation glaucoma
(Medical College of Georgia at Augusta University) In exfoliation glaucoma, a protein dandruff clogs the outflow pathway for the fluid in our eyes.Scientists have evidence that variants of the same gene that enables us to make connective tissue by crosslinking proteins is associated with this unusual glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Pfizer Hikes Cost Of Viagra And 100 Other Drugs, Report Says
(CBS News) — A month after President Donald Trump signaled drug companies would soon be slashing prices, the nation’s largest pharmaceutical company is reportedly upping the costs of 100 drugs and treatments. Pfizer has increased the price of some of its better-known drugs, including the erectile dysfunction treatment Viagra, according to a story published Monday by the Financial Times. The increases, which took effect July 1, are just over 9 percent on average, well above the rate of inflation, which is about 2 percent. It’s the second such move this year by Pfizer, with the cost of some of its drugs up ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 2, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Local TV Pfizer Source Type: news

Novartis and Alcon to Separate
Novartis said it plans to spin out its Alcon Division into a separately-traded company. The move will allow the Basel, Switzerland-based company and Alcon to focus on respective growth strategies. If the split meets general market conditions, regulatory approvals, final Board of Directors endorsement, and shareholder approval then the planned separation could be completed by the first half of 2019. Novartis said if the Alcon spin out is completed, then it would create a new Switzerland-based company with global scale and reach comprising more than 20,000 employees, with around $7 billion in 2017 sales. The firm said that i...
Source: MDDI - June 29, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Glaucoma Surgery Space Heats Up with New Approval
Glaukos has received FDA approval to market the iStent inject Trabecular Micro-Bypass System. The nod gives the San Clementa, CA-based company an opportunity to pull ahead of competition in the minimally invasive glaucoma surgery (MIGS) market. Glaukos said the iStent inject is designed to optimize the natural physiological outflow of aqueous humor by creating two patent bypasses through the trabecular meshwork, the main source of resistance in glaucomatous eyes, resulting in multi-directional flow through Schlemm’s canal. It includes two heparin-coated titanium stents preloaded into an auto-injection syst...
Source: MDDI - June 25, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Glaukos wins FDA PMA for iStent inject glaucoma device
Glaukos (NYSE:GKOS) said today it won FDA premarket approval for its iStent inject trabecular micro-bypass system. With the clearance, the iStent inject is now indicated for use in the reduction of intraocular pressure in adults with mild to moderate primary open-angle glaucoma who are undergoing concomitant cataract surgery. San Clemente, Calif.-based Glaukos said the iStent inject is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It uses a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows them to be injected into multiple trabecu...
Source: Mass Device - June 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pre-Market Approval (PMA) Regulatory/Compliance Glaukos Source Type: news

Medical News Today: Persistent stress may lead to vision loss, study shows
A new analysis of existing studies shows that persistent psychological stress can lead to conditions such as glaucoma, retinal neuropathy, and vision loss. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2018 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

A stressful job could leave you blind: Psychological pressure can cause vision loss, scientists warn
Stress can bring on or worsen vision problems and even lead to blindness because of conditions like glaucoma and diabetes, according to research by Magdeburg University in Germany. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2018 Category: Consumer Health News Source Type: news

UH scientist working toward a glaucoma cure
(University of Houston) With $765,000 from the National Institutes of Health, University of Houston College of Optometry biomedical engineer Vijaykrishna Raghunathan is working towards a pharmaceutical cure for the irreversible disease Glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2018 Category: International Medicine & Public Health Source Type: news